Last reviewed · How we verify

JTZ-951 — Competitive Intelligence Brief

JTZ-951 (JTZ-951) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Apelin receptor antagonist. Area: Cardiovascular.

phase 3 Apelin receptor antagonist APJ (apelin receptor) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

JTZ-951 (JTZ-951) — JW Pharmaceutical. JTZ-951 is a selective antagonist of the apelin receptor (APJ) that modulates cardiovascular and metabolic pathways.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
JTZ-951 TARGET JTZ-951 JW Pharmaceutical phase 3 Apelin receptor antagonist APJ (apelin receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Apelin receptor antagonist class)

  1. JW Pharmaceutical · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). JTZ-951 — Competitive Intelligence Brief. https://druglandscape.com/ci/jtz-951. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: